Stéphane Piat, Managing Director of CARMAT, comments: “This agreement in principle with the EIB on new loan repayment terms is a positive signal for the Company.”
Subject to the fulfillment of the suspensive conditions, this agreement will allow us to avoid any repayment under this loan, at least until July 31, 2026, and thus to put our financial resources primarily at the service of our growth. I would like to thank the EIB for its commitment to us, renewed today.
The Company’s management and teams are more determined than ever to continue their march forward to make Aeson® the reference therapy in advanced biventricular heart failure, enable CARMAT to become the leader in this segment, and thus offering a solution to the many patients who are today in a therapeutic impasse. »
To receive all CARMAT financial information in real time, request it by email to [email protected]. Your registration will be immediate.